• Description
• Additional information
• Reviews (0)

SEMA-BPC-157 COMBINATION

U.S. Regulatory & Scientific Research Reference – Updated July 24, 2026

FOR EDUCATIONAL AND PROFESSIONAL REFERENCE ONLY | Not a product listing | NOT a clinical or preparation protocol

Regulatory Status – Read Before Proceeding

Sema is FDA-approved (Ozempic®, Wegovy®, Rybelsus® – Novo Nordisk). BPC-157 is NOT FDA-approved for any human indication in the United States as of July 2026. No NDA, BLA, or ANDA exists for BPC-157, and no FDA-approved fixed-combination product containing both Sema and BPC-157 exists in any form. BPC-157 IS A PEPTIDE; SEMA IS A PEPTIDE. Both are synthetic amino-acid-chain compounds, but they sit in entirely different regulatory frameworks: Sema is an approved finished drug product; BPC-157 has been evaluated only under FDA’s Section 503A bulk drug substance framework (Category 1/2/3) and the Pharmacy Compounding Advisory Committee (PCAC) process. PCAC VOTE (July 23, 2026): FDA’s Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend adding BPC-157 (free base and acetate) to the 503A Bulks List for ulcerative colitis – despite FDA career-staff briefing documents recommending against inclusion. This vote is advisory and non-binding; it is not FDA approval and does not itself authorize compounding. Formal rulemaking has not concluded. COMPOUNDING STATUS: Following resolution of the Sema drug-shortage listing (February 2025) and expiration of enforcement-discretion windows (April–May 2025), compounding of Sema that is “essentially a copy” of an approved product is prohibited absent documented, patient-specific medical necessity. BPC-157 has no lawful 503A or 503B compounding pathway as of this writing. PATENT DISCLOSURE: A published U.S. patent application (US20240382565A1, assigned to Red Mountain Holdings, LLC) discloses a sublingual formulation combining Sema sodium salt and BPC-157 acetate. Grant status, grant number, and current legal status should be independently verified against the USPTO Patent Full-Text and Image Database before any external citation. WADA STATUS: BPC-157 is classified under S0 (Non-Approved Substances) on the WADA Prohibited List and is prohibited at all times, with no Therapeutic Use Exemption pathway. Sema is not on the WADA Prohibited List. This document is a scientific and regulatory reference only. It is not a product listing, clinical protocol, preparation guide, dosing recommendation, or consumer recommendation, and does not constitute medical or legal advice.

Product overview

Sema and BPC-157 are two synthetic peptides that occupy fundamentally different positions in U.S. drug regulation, yet are increasingly discussed together in peptide-market and weight-management content. Sema is anchored at PubChem CID 56843331 (C₁₈₇H₂₉₁N₄₅O₅₉; CAS 910463-68-2; MW ≈ 4,113.6 g/mol) and is FDA-approved as the active ingredient in Ozempic®, Wegovy®, and Rybelsus®. BPC-157 is anchored at PubChem CID 9941957 (C₆₂H₉₈N₁₆O₂₂; CAS 137525-51-0; MW ≈ 1,419.56 g/mol) and remains an investigational compound with no completed Phase II/III human efficacy trials and no FDA-approved finished drug product. The two compounds are discussed in combination almost exclusively because of a proposed mechanistic rationale: BPC-157’s preclinical gastric-cytoprotective profile is hypothesized – without controlled human evidence – to mitigate the gastrointestinal side effects associated with Sema therapy. As of July 2026, no registered or published randomized clinical trial has evaluated this combination in humans, and no FDA-approved fixed-combination product containing both agents exists. This reference distinguishes the two compounds’ regulatory identities, summarizes the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) proceedings, documents the disclosed sublingual-combination patent application, and outlines the litigation, digital-advertising, and anti-doping environment relevant to any U.S. peptide-market content strategy involving these two compounds. BPC-157 chemical structure – PubChem CID 9941957 – synthetic pentadecapeptide (gastric cytoprotective research compound) – molecular formula C62H98N16O22 – CAS 137525-51-0 -U.S. regulatory reference 2026. Sema chemical structure – PubChem CID 56843331 – GLP-1 receptor agonist peptide – molecular formula C187H291N45O59 – CAS 910463-68-2 – U.S. regulatory reference 2026.

Chemical Identity – Compound Registry and Structural Reference

The table below provides verified PubChem CIDs, CAS numbers, molecular formulas, and molecular weights for both compounds and their salt forms referenced in the disclosed combination patent.

Sources: PubChem CID 56843331, 172871828, 9941957, 155977614; CAS registry data cross-checked against Wikidata and commercial chemical-supplier records.

Mechanism of Action and Combination Rationale

Evidence Base – Indexed Human and Preclinical Literature (2021–2026)

FDA Regulatory Timeline (2022 – July 24, 2026)

Comparative Regulatory Status: Sema vs. BPC-157

Patent Disclosure – Sublingual Sema + BPC-157 Formulation

U.S. patent application US20240382565A1, “Sublingual Sema-BPC 157 Combination for Weight Loss,” is assigned to Red Mountain Holdings, LLC and discloses a solid oral composition for sublingual delivery combining Sema sodium salt and BPC-157 acetate. The stated rationale is bypassing first-pass hepatic metabolism and the enzymatic environment of the proximal small intestine, given the generally poor oral bioavailability of peptide therapeutics. Verification flag: confirm current legal status, any grant number, and assignee-of-record directly on the USPTO Patent Full-Text and Image Database or Google Patents before citing a granted-patent number in published content.

The patent application also discloses aggregate daily usage ranges for both active components. These figures are reported strictly as a description of the patent document and are not a recommended, approved, or clinically validated dosing protocol. Commercializing a compounded combination matching this patent disclosure currently constitutes a violation of federal compounding law. FDA has stated that Sema sodium and Sema acetate possess different chemical and pharmacologic properties than the FDA-approved base ingredient in Wegovy®/Ozempic®, with no lawful compounding basis.

Why This Combination

The Sema + BPC-157 pairing appears in peptide-vendor and clinic content almost entirely because of two mechanistic hypotheses, neither confirmed in controlled human research. First, Sema’s GLP-1 receptor activity slows gastric emptying, which is the mechanism behind its most commonly reported gastrointestinal side effects; BPC-157’s preclinical profile in rodent models is invoked as a theoretical counterbalance to that GI intolerance. Second, rapid metabolic change during GLP-1 therapy has been associated with joint and connective-tissue discomfort in some patients, and BPC-157’s preclinical tendon- and muscle-healing data are cited as a rationale for pairing the two. Both arguments originate from extrapolating animal-model findings onto a human combination that has never been tested together in any registered clinical trial.

Litigation and Enforcement Environment

Adverse Event Reporting (FAERS, as reported mid-2026)

Manufacturer and Regulatory Enforcement Actions

• Since mid-2025, Novo Nordisk has filed 130+ lawsuits across 40 states against telehealth companies, compounding pharmacies, and medical spas, alleging trademark infringement, false advertising, unfair competition, and violations of the corporate-practice-of-medicine doctrine.
• March 2026: Hims & Hers Health settled its patent-infringement dispute with Novo Nordisk, agreeing to shift toward distributing Novo Nordisk’s branded, FDA-approved Sema products.
• Early 2026: Strive Compounding Pharmacy filed an antitrust suit against Eli Lilly and Novo Nordisk, alleging exclusionary agreements with telehealth platforms.
• July 2026: Novo Nordisk filed a Lanham Act suit against Eli Lilly in the U.S. District Court for the District of New Jersey over GLP-1 advertising comparisons.
• September 2025: FDA issued 50+ warning letters to GLP-1 compounders/manufacturers; March 2026: 30 additional warning letters to telehealth companies implying compounded-product equivalence to approved drugs.
• April 7, 2026: FDA published a cluster of seven warning letters against online peptide sellers relying on “research use only” disclaimers, establishing that intended use — not labeling — determines drug status under FFDCA §201(g)(1).

Why Profound Aminos

Profound Aminos operates as a research-use-only (RUO) peptide reference resource built around the same compliance framework applied throughout this document: verified regulatory status, PubChem-anchored chemical identity, and peer-reviewed literature, not therapeutic marketing claims.

• Compliance-first content: every product reference separates FDA-approved compounds from investigational research peptides, avoids “treats/cures/heals” language, and discloses current 503A/503B and PCAC status rather than implying approval where none exists.
• Documentation-forward: each listing is built to be paired with certificate of analysis / third-party testing documentation for research traceability.
• Regulatory tracking: content is reviewed and updated as FDA, PCAC, and WADA status changes, consistent with this document’s July 2026 update cycle.
• Research-only positioning: products are described strictly for laboratory and research use, aligned with FDA’s intended-use enforcement standard — not for self-administration or consumer health claims.

Compliance-safe content practice

Strip therapeutic-claim language (treats, cures, heals) from all product-adjacent pages; separate Sema (approved drug) and BPC-157 (unapproved research peptide) as distinct entities; avoid presenting the two as a validated stack or protocol; cite peer-reviewed and FDA/PubChem primary sources; attribute content to verifiably credentialed authors.

WADA / USADA Anti-Doping Status

Compliance-Safe Content Guidelines (RUO / Education Only)

Prohibited Claims and Angles

• Promoting sema/BPC-157 as a therapy, stack, or protocol for metabolic support, injury healing, or GI conditions.
• Suggesting BPC-157 can safely or effectively prevent Sema-related side effects in humans.
• Providing dosing, injection instructions, or cycle designs for the combination.
• Targeting athletes with combination messaging, given BPC-157’s WADA S0 status.

Acceptable Educational Angles

• Descriptive comparison of Sema’s evidence-based approvals vs. BPC-157’s preclinical/PCAC-review status.
• Explanation of the July 23–24, 2026 PCAC proceedings, including the staff-vs-committee-vote divergence and the non-binding nature of the vote.
• Overview of WADA S0 rules and why unapproved peptides like BPC-157 are banned for athletes.
• High-level discussion of how speculative combination narratives appear in clinic/vendor marketing versus what regulators and controlled evidence actually show.

Frequently Asked Questions – Scientific and Regulatory Reference

Q1: Is there an FDA-approved Sema + BPC-157 combination product? No. Sema is FDA-approved as a standalone active ingredient (Ozempic®, Wegovy®, Rybelsus®). BPC-157 is not FDA-approved for any indication. No fixed-combination drug product containing both agents has been approved; a patent application discloses such a formulation, which is distinct from drug approval. Q2: What happened at the July 23–24, 2026 PCAC meeting? FDA’s Pharmacy Compounding Advisory Committee reviewed seven bulk peptide substances, including BPC-157, for potential addition to the 503A Bulks List. FDA career-staff briefing documents recommended against inclusion of all seven. The committee nonetheless voted 8–6 (one abstention) to recommend adding BPC-157. The vote is advisory and non-binding. Q3: Does the PCAC vote make BPC-157 legal to compound? No. A PCAC recommendation is not FDA action. Formal notice-and-comment rulemaking would still be required, and FDA is not obligated to adopt the committee’s recommendation. Q4: Is BPC-157 legal to sell as a dietary supplement or “research use only” product? No. BPC-157 is not a lawful dietary supplement under DSHEA. FDA’s enforcement position is that intended use – not “RUO” labeling – determines whether a product is regulated as an unapproved new drug. Q5: Can compounded Sema still be dispensed legally? Only in narrow circumstances: a documented, individualized medical necessity not met by the approved product, such as a verified inactive-ingredient allergy, a clinically justified need for a non-commercial concentration, or a required dosage-form modification for a specific patient population. Cost and patient preference are not recognized as medical necessity. Q6: What is the WADA status of each compound? BPC-157 is classified S0 and is prohibited at all times for athletes subject to WADA/USADA codes, with no Therapeutic Use Exemption pathway. Sema is not on the WADA Prohibited List and is generally permitted under standard medical-disclosure rules. Q7: Is there human clinical evidence supporting the Sema + BPC-157 combination? No. No registered or published randomized controlled trial has evaluated the combination in humans for weight loss, joint protection, or GI outcomes. The rationale for pairing the two compounds is mechanistic speculation. Q8: What does the disclosed patent application actually claim? Published U.S. application US20240382565A1 discloses a sublingual tablet combining Sema sodium salt and BPC-157 acetate, with specified excipient and dosage ranges. A patent application is not equivalent to FDA approval, clinical validation, or a lawful compounding pathway. Q9: Why are Sema and BPC-157 moving in opposite regulatory directions? Sema is moving toward tighter restriction on compounded and generic-adjacent versions following shortage resolution. BPC-157 is moving toward a narrow, still-pending compounding opening via the 503A Bulks List process, contingent on FDA follow-through after the July 2026 PCAC vote. Q10: What content framing is appropriate for a U.S. audience discussing this combination? Content should clearly separate the two compounds by regulatory status and evidence quality, avoid therapeutic or “stack” claims, disclose that no combination is FDA-approved or clinically validated, cite PMID-anchored primary literature and FDA/PubChem sources, and avoid consumer-directed dosing or administration guidance.

Regulatory and Compliance Statement – Scientific Reference Document

Verification Checklist -For Manual Review Before Publication

• Confirm the exact date FDA removed BPC-157 from Category 2 – check the FDA 503A bulk drug substances page directly.
• Confirm the actual public-comment deadline for the 503B exclusion proposal – check the Federal Register docket.
• Confirm whether patent application US20240382565A1 has issued as a granted patent, and if so, the correct patent number, grant date, and current assignee of record.
• Confirm the entity name associated with the sublingual-combination patent.
• Confirm the exact outcome and vote count of the July 23–24, 2026 PCAC meeting directly against the official FDA meeting minutes/transcript once published.
• Confirm current LegitScript certification fee figures before publishing specific dollar amounts.
• Re-verify all market-sizing figures against the named research-firm reports directly.

Key References – PubChem / FDA / PubMed / USPTO / WADA – Compiled July 2026

• 18.8% weight loss at 72 weeks) in favor of outdated comparisons; Lilly points to the Surmount-5 head-to-head trial in its
• 1. PubChem CID 56843331 – Sema. pubchem.ncbi.nlm.nih.gov/compound/Sema – C₁₈₇H₂₉₁N₄₅O₅₉; CAS 910463-
• 2. PubChem CID 172871828 -Sema (sodium salt). pubchem.ncbi.nlm.nih.gov/compound/Sema-_sodium-salt
• 3. PubChem CID 9941957 – BPC-157. pubchem.ncbi.nlm.nih.gov/compound/Bpc-157 – C₆₂H₉₈N₁₆O₂₂; CAS 137525-51-0.
• 4. PubChem CID 155977614 – BPC-157 acetate. pubchem.ncbi.nlm.nih.gov/compound/BPC-157-acetate
• 5. US20240382565A1 – Sublingual Sema-BPC 157 combination for weight loss – Google Patents.
• 6. U.S. Food and Drug Administration – July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (Docket
• 7. FDA – FDA Proposes to Exclude Sema, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026 press
• 8. Orrick LLP – FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs (May 1, 2026).
• 9. Orrick LLP – FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting (2026).
• 10. ClinicalTrials.gov NCT07437547 – Phase 2 RCT of Pentadecapeptide BPC-157 for Acute Grade II Hamstring Strain.
• 11. World Anti-Doping Agency – The 2026 Prohibited List (effective January 1, 2026). wada-ama.org/en/prohibited-list
• 12. Lee E, Burgess S. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med.
• 13. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025.
• 14. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157. PMC12446177 (2025).
• 15. Yuan C, et al. The Role of BPC-157 in Tissue Repair and Pain Management. PMC13026520 (2026).
• 16. Matek D, et al. Tendon, Ligament, and Muscle Injury, Osteotendinous Junctions. PMC12944561 (2026).
• 17. Pevec D, et al. Impact of pentadecapeptide BPC 157 on muscle healing. europepmc.org/article/med/20190676 (2010).
• 18. Novo Nordisk – Compounding Letter to Healthcare Professionals.
• 19. Novo Nordisk, Eli Lilly Sending Cease-and-Desist Letters Over Compounded Sema – HCH Lawyers.
• 20. FDA Crackdown on Telehealth Advertising: Compounded Drug Marketing Compliance – Frier Levitt.
• 21. Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons – PharmExec.
• 22. From Crackdown to Collaboration: FDA Warning Letters and the Hims-Novo Nordisk Deal – Frier Levitt.
• 23. Compounding Pharmacy Sues Eli Lilly, Novo Nordisk Over Alleged GLP-1 Antitrust Violations – HMP Global Learning
• 24. Google – Healthcare & medicines policy – Merchant Center Help. support.google.com/merchants/answer/6150151
• 25. Google – Unapproved pharmaceuticals and supplements – Advertising Policies Help.
• 26. LegitScript – Healthcare Certification: Operate Safely Online. legitscript.com/certification/healthcare-certification/
• 27. LegitScript – Understanding Peptides (Peptides for Payment Processors Guide). legitscript.com/wp-
• 28. FDA – Certain Bulk Drug Substances for Use in Compounding / 503A framework. fda.gov/drugs/human-drug-compounding/

Scientific Reference Document | Educational and Professional Use Only

Sema is FDA-approved; BPC-157 is NOT FDA-approved. No combination product is FDA-approved. This document is not a product listing. No consumer or self-directed use is implied or recommended.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

DISCLAIMER:

• Products sold on our website are meant for scientific research purposes only, designed for in vitro testing and lab experimentation exclusively. These products are not intended to be used as foods, drugs or cosmetics, any sort of bodily introduction of the products into humans or animals is strictly prohibited. They must also not be misbranded, misused, or mislabeled, or used for anything other than research and scientific investigation.
• All the products you see on the website are being sold in a lyophilized powder state (freeze-dried), in a sealed sterile vial; and should be reconstituted.
  The product’s label clearly states the amount of product a vial contains; some products are offered in different variations.
• The products we are selling come in a sealed vial but require additional lab equipment for proper testing. 
• Though we make sure packaging, label, seals and writing does not differ from the product photos you see on our website, there is a chance for a minimal deviation.